Eravacycline Activity Against KPC-2- and NDM-1-Producing Klebsiella Pneumoniae

42 Klebsiella pneumoniae strains co-producing KPC-2 and NDM-1 were analyzed for susceptibility to eravacycline and combination therapies. The dataset contains in vitro and in vivo results from a Galleria mellonella infection model, authored by Xiaojie Zhao and published in 2026.

Use Cases

• Analyze eravacycline MIC50/90 values and susceptibility rates across 42 K2N1-CRKP strains.
• Evaluate synergistic activity of eravacycline-polymyxin B combinations using in vitro time-kill assay results.
• Compare survival benefit outcomes from monotherapy versus combination therapy in the Galleria mellonella model.

Strengths

• Data covers 42 distinct K2N1-CRKP strains for statistical analysis.
• Includes both in vitro (MIC, time-kill assays) and in vivo (Galleria mellonella model) activity results.
• Provides specific MIC metrics (MIC50/90: 1 μg/mL; range: 0.5–2 μg/mL) for eravacycline.

Limitations

• Small sample size of 42 strains limits generalizability of findings.
• Data is restricted to a single bacterial sequence type (ST11).
• The 32.5 KB file size indicates limited scope and detail.

Provenance

Source

Xiaojie Zhao

Collection Method

Laboratory analysis of clinical isolates, including susceptibility testing and animal infection modeling.

Freshness

Last updated March 2026.